

# Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G29F0BFED41AEN.html>

Date: October 2021

Pages: 150

Price: US\$ 2,400.00 (Single User License)

ID: G29F0BFED41AEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:

Research Methodology

Global & Regional Market Analysis

Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion

Market & Drug Sales Insight 2020 Till 2026

Approved Drug In Market: 2 (Lartruvo & Ayvakit)

Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026

Future market Assessment By Indication & Region Till 2026

Ongoing Clinical Trials Assessment by Status, Phase & Region

Key Market Dynamics

Competitor Landscape

Platelet derived growth factor (PDGF) are the members of growth factor receptors which are found to be overexpressed in many cancers, correlating with reduced overall survival. In some cancer types, PDGF receptors are expressed on non-cancerous cells of the tumor microenvironment or tumor stroma that are able to crosstalk with cancer and thus have critical role in the development of cancer. Over the time, it has emerged out to be an important target for the drug therapies intended for treatment wide range of cancers.

Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since its introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years.

In the same year, Ripretinib sold under brand name Qinlock has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limit their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.

Presently, several companies including well-established players and new entrants are actively engaged in developing PGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. This sector has particularly gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market also witnessed substantial partnership activity over the last few years.

In coming years, the global market will witness significant rise in the prevalence of cancers attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity, and poor diet. This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market. In addition to two approved drugs, the pharmaceutical companies have developed several potential

PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are expected to enter the market during the forecast period, thus boosting the growth of market.

As per report findings, the global PDGFR inhibitor market will grow with CAGR of 92% and is expected to reach around US\$ 4 Billion by 2026. The high growth in the market can be justified by the extensive research and development in this sector and high adoption rates of approved drugs. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. Regionally, US is expected to dominate the market owing to large target population base, increasing adoption rates to novel therapies, and high concentration of pharmaceutical companies which actively indulge in research and development sector. Apart from this, Asia-Pacific region is also expected to exhibit high CAGR rates due to increased healthcare spending and presence of several untapped opportunities.

## Contents

### **1. INTRODUCTION TO PDGFR INHIBITORS**

- 1.1 Overview
- 1.2 Evolution of PDGFR Inhibitors

### **2. PDGFR INHIBITORS - MECHANISM OF ACTION**

- 2.1 General Functions & Mechanism
- 2.2 Approved Drugs Mechanism of Action

### **3. PDGFR POTENTIAL TARGET FOR LEADING PATHOLOGICAL CONDITIONS**

### **4. ROLE OF PDGFR INHIBITORS IN CANCER**

### **5. GLOBAL PDGFR INHIBITORS CLINICAL TRIALS INSIGHT**

- 5.1 By Phase
- 5.2 By Development Status
- 5.3 By Region

### **6. GLOBAL PDGFR INHIBITOR MARKET INSIGHT**

- 6.1 Market Overview
- 6.2 Current Market Scenario

### **7. PDGFR INHIBITOR REGIONAL MARKET ANALYSIS**

- 7.1 US
- 7.2 Europe
- 7.3 China
- 7.4 Japan
- 7.5 ROW

### **8. PDGFR INHIBITOR MARKET OPPORTUNITY BY INDICATION**

- 8.1 Gastrointestinal Stromal Tumors
- 8.2 Glioma

8.3 Colorectal Cancer

8.4 Leukemia

8.5 Lung Cancer

## **9. LARTRUVO (OLARATUMAB) 1ST APPROVED PDGFR INHIBITOR (2016) & MARKET WITHDRAWAL (2019)**

9.1 Overview

9.2 Dosage, Price & Sales Analysis

## **10. AYVAKIT (AVAPRITINIB) 2ND APPROVED PDGFR INHIBITOR (2020)**

10.1 Overview

10.2 Patents & Assignees

## **11. AYVAKIT COMMERCIAL INSIGHT**

11.1 Price & Dosage

11.2 Sales Analysis

## **12. QINLOCK (RIPRETINIB) 3RD APPROVED PDGFR INHIBITOR (2020)**

12.1 Overview

12.2 Patents & Assignees

## **13. QINLOCK COMMERCIAL INSIGHT**

13.1 Price & Dosage

13.2 Sales Analysis

## **14. PDGFR INHIBITORS SALES FORECAST 2026**

14.1 Ayvakit Sales Forecast

14.2 Qinlock Sales Forecast

## **15. PDGFR INHIBITOR FUTURE MARKET PERSPECTIVES**

## **16. GLOBAL PDGFR INHIBITORS MARKET DYNAMICS**

16.1 Market Drivers

16.2 Market Challenges

## **17. COMPETITIVE LANDSCAPE**

17.1 Arog Pharmaceuticals, Inc

17.2 AstraZeneca

17.3 Bayer

17.4 Blueprint Medicine

17.5 Boehringer Ingelheim

17.6 Clovis Oncology

17.7 Deciphera Pharmaceuticals

17.8 Eli Lilly

17.9 Gilead Sciences

17.10 Pfizer

17.11 Tyrogenex

17.12 Zai Lab

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Evolution of PDGFR Inhibitors
- Figure 2-1: PDGFR's Pathway, Receptors, Ligands & Functions
- Figure 2-2: PDGFR Stimulated Effectors, Biomarkers & Cell Signaling Pathways
- Figure 2-3: PDGFR Inhibitors – Mechanism of Action
- Figure 2-4: Ayvakit - Mechanism of Action
- Figure 2-5: Qinlok – Mechanism of Action
- Figure 2-6: Lartruvo – Mechanism of Action
- Figure 3-1: Role of PDGFR Inhibitors in Neurological Disorders
- Figure 3-2: Potential Role of PDGFR Inhibitors in Asthma
- Figure 4-1: PDGF Signaling in Cancer Progression
- Figure 5-1: Global – Number of PDGFR Inhibitors Related Clinical Trials by Phase, October'2021
- Figure 5-2: Global – PDGFR Inhibitors Related Clinical Trials by Phase (%), October'2021
- Figure 5-3: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status, October'2021
- Figure 5-4: Global – Number of PDGFR Inhibitors Related Clinical Trials by Development Status (%), October'2021
- Figure 5-5: Global – Number of PDGFR Inhibitors Related Clinical Trials by Region, October'2021
- Figure 6-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 6-2: Global – PDGFR Inhibitor Market by Product (%), 2020
- Figure 6-3: Global – PDGFR Inhibitor Market by Product (%), H1'2021
- Figure 6-4: Global – PDGFR Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 6-5: PDGFR Inhibitor - Market by Region (US\$ Million), 2020
- Figure 6-6: PDGFR Inhibitor - Market by Region (%), 2020
- Figure 6-7: PDGFR Inhibitor - Market by Region (US\$ Million), H1'2021
- Figure 6-8: PDGFR Inhibitor - Market by Region (%), H1'2021
- Figure 7-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 7-2: PDGFR Inhibitor Market – US vs. ROW (US\$ Million), 2020
- Figure 7-3: PDGFR Inhibitor Market – US vs. ROW (%), 2020
- Figure 7-4: PDGFR Inhibitor Market – US vs. ROW (US\$ Million), H1'2021
- Figure 7-5: PDGFR Inhibitor Market – US vs. ROW (%), H1'2021
- Figure 7-6: US – PDGFR Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 7-7: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025

- Figure 7-8: Europe – Cancer Incidences by Country (Million), 2020
- Figure 7-9: PDGFR Inhibitor Market – Europe vs. ROW (US\$ Million), 2020
- Figure 7-10: PDGFR Inhibitor Market – Europe vs. ROW (%), 2020
- Figure 7-11: Europe – PDGFR Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 7-12: China – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 7-13: China – PDGFR Inhibitor Market Size (US\$ Million), 2021 - 2026
- Figure 7-14: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 7-15: Japan – PDGFR Inhibitor Market Size (US\$ Million), 2022 - 2026
- Figure 7-16: Cancer – Incidences by Region, 2020
- Figure 7-17: ROW – PDGFR Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 8-1: Global – Estimated GIST Cancer Cases, 2020 - 2026
- Figure 8-2: Global – PDGFR Inhibitor Market Opportunity in GIST by 5% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-3: Global – PDGFR Inhibitor Market Opportunity in GIST by 10% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-4: Global – PDGFR Inhibitor Market Opportunity in GIST by 15% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-5: Global – PDGFR Inhibitor Market Opportunity in GIST by 20% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-6: Global – PDGFR Inhibitor Market Opportunity in GIST by 25% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-7: Global – PDGFR Inhibitor Market Opportunity in GIST by 30% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-8: Global – PDGFR Inhibitor Market Opportunity in GIST by 35% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-9: Global – PDGFR Inhibitor Market Opportunity in GIST by 40% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-10: Global – PDGFR Inhibitor Market Opportunity in GIST by 45% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-11: Global – PDGFR Inhibitor Market Opportunity in GIST by 50% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-12: Global – Estimated Glioma Cancer Cases, 2020 - 2026
- Figure 8-13: Global – PDGFR Inhibitor Market Opportunity in Glioma by 2% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-14: Global – PDGFR Inhibitor Market Opportunity in Glioma by 4% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-15: Global – PDGFR Inhibitor Market Opportunity in Glioma by 6% Adoption Rate (US\$ Million), 2021 - 2026
- Figure 8-16: Global – PDGFR Inhibitor Market Opportunity in Glioma by 8% Adoption



Rate (US\$ Million), 2021 - 2026

Figure 8-17: Global – PDGFR Inhibitor Market Opportunity in Glioma by 10% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-18: Global – PDGFR Inhibitor Market Opportunity in Glioma by 12% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-19: Global – PDGFR Inhibitor Market Opportunity in Glioma by 14% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-20: Global – PDGFR Inhibitor Market Opportunity in Glioma by 16% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-21: Global – PDGFR Inhibitor Market Opportunity in Glioma by 18% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-22: Global – PDGFR Inhibitor Market Opportunity in Glioma by 20% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-23: Global – Estimated Colorectal Cancer Cases, 2020-2026

Figure 8-24: Global – Estimated Metastatic Colorectal Cancer Cases, 2020-2026

Figure 8-25: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 1% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-26: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 2% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-27: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 3% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-28: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 4% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-29: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 5% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-30: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 6% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-31: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 7% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-32: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 8% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-33: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 9% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-34: Global – PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 10% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-35: Global – Estimated Leukemia Cancer Cases, 2020 - 2026

Figure 8-36: Global – Estimated Acute Myeloid Leukemia Cancer Cases, 2020 - 2026

Figure 8-37: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 1% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-38: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 2% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-39: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 3% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-40: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 4% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-41: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 5% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-42: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 6% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-43: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 7% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-44: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 8% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-45: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 9% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-46: Global – PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 10% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-47: Global – Estimated Lung Cancer Cases, 2020 - 2026

Figure 8-48: Global – Estimated PDGFR Mutated Lung Cancer Cases, 2021 - 2026

Figure 8-49: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 1% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-50: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 2% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-51: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 3% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-52: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 4% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-53: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 5% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-54: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 6% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-55: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 7% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-56: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 8% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-57: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 9% Adoption Rate (US\$ Million), 2021 - 2026

Figure 8-58: Global – PDGFR Inhibitor Market Opportunity in Lung Cancer by 10%

Adoption Rate (US\$ Million), 2021 - 2026

Figure 9-1: Lartruvo – Approval Year by Region

Figure 9-2: Lartruvo – FDA Approval & Orphan Designation Year

Figure 9-3: Lartruvo – Compound Patent & Biological Data Package Protection  
Expiration Year

Figure 9-4: Lartruvo – Market Approval & Withdrawal Year

Figure 9-5: Lartruvo – Price for 19ml Supply & Price per ml of Intravenous Solution  
(US\$), October'2021

Figure 9-6: Lartruvo – Price for 50ml Supply & Price per ml of Intravenous Solution  
(US\$), October'2021

Figure 9-7: Lartruvo – Average Cost of Single Dose & Single Treatment Cycle (US\$),  
October'2021

Figure 9-8: Global – Lartruvo Annual Sales (US\$ Million), 2017 & 2018

Figure 10-1: Ayvakit – Orphan Drug Designation by Region

Figure 10-2: US - Ayvakit FDA Approval Year by Indication

Figure 10-3: Ayvakit – Approval Year by Region

Figure 10-4: US – Ayvakit Patent Approval & Expiration Year

Figure 11-1: US – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet  
(US\$), October'2021

Figure 11-2: Europe – Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral  
Tablet (Euro/US\$), October'2021

Figure 11-3: Ayvakit – Recommended Initial & Reduced Dose in Patients with GIST  
(mg)

Figure 11-4: US – Average Cost of Daily, Monthly & Annual Treatment with Ayvakit  
(US\$)

Figure 11-5: Global – Ayvakit Quarterly Sales (US\$ Million), 2020

Figure 11-6: Global – Ayvakit Quarterly Sales (US\$ Million), Q1 - Q3'2021

Figure 12-1: US - Qinlock Orphan Drug Designation & FDA Approval Year

Figure 12-2: Qinlock – Approval Year by Region

Figure 12-3: US – Qinlock Patent Approval & Expiration Year

Figure 12-4: Canada - Qinlock Patent Approval & Expiration Year

Figure 13-1: US – Cost of Supply of 90 Tablets & Per Unit Cost of Qinlock 50mg Oral  
Tablet (US\$), October'2021

Figure 13-2: Qinlock – Recommended Initial & Reduced Dose in Patients with GIST  
(mg)

Figure 13-3: US – Average Cost of Daily, Monthly & Annual Treatment with Qinlock  
(US\$)

Figure 13-4: Global – Qinlock Quarterly Sales (US\$ Million), Q2-Q4'2020

Figure 13-5: US – Qinlock Quarterly Sales (US\$ Million), Q2-Q4'2020

Figure 13-6: Qinlock Quarterly Sales by Region (US\$ Million), Q2-Q4'2020

Figure 13-7: Qinlock Quarterly Sales by Region (%), Q2-Q4'2020

Figure 13-8: Global – Qinlock Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 13-9: US – Qinlock Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 13-10: Qinlock – Half Year Sales by Region (US\$ Million), H1'2021

Figure 13-11: Qinlock – Half Year Sales by Region (%), H1'2021

Figure 14-1: Global – Ayvakit Sales Forecast (US\$ Million), 2021 - 2026

Figure 14-2: Global – Qinlock Sales Forecast (US\$ Million), 2021 - 2026

Figure 14-3: US – Qinlock Sales Forecast (US\$ Million), 2021 - 2026

Figure 14-4: ROW – Qinlock Sales Forecast (US\$ Million), 2021 - 2026

Figure 16-1: Global PDGFR Inhibitors Market Drivers

Figure 16-2: Challenges for Global PDGFR Inhibitors Market

Figure 16-3: US – Annual Treatment Cost Comparison of PDGRF Inhibitors with Other Treatments (US\$), October'2021

## List Of Tables

### LIST OF TABLES

Table 4-1: Frequency of PDGFR by Cancer Types

Table 8-1: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026

Table 8-2: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026

Table 8-3: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026

Table 8-4: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026

Table 8-5: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 – 2026

## I would like to order

Product name: Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G29F0BFED41AEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G29F0BFED41AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970